Zacks Research Brokers Boost Earnings Estimates for AbbVie

AbbVie Inc. (NYSE:ABBV) – Equities researchers at Zacks Research lifted their Q1 2026 EPS estimates for AbbVie in a research note issued to investors on Wednesday, January 14th. Zacks Research analyst Team now anticipates that the company will post earnings of $3.01 per share for the quarter, up from their prior forecast of $2.94. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q2 2026 earnings at $3.71 EPS, Q3 2026 earnings at $3.76 EPS, FY2026 earnings at $14.18 EPS, Q1 2027 earnings at $3.27 EPS, Q2 2027 earnings at $4.03 EPS, Q3 2027 earnings at $4.30 EPS and FY2027 earnings at $15.75 EPS.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

ABBV has been the topic of a number of other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. UBS Group restated a “neutral” rating on shares of AbbVie in a research report on Tuesday. Scotiabank assumed coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, Raymond James Financial set a $256.00 price objective on AbbVie in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $247.84.

AbbVie Stock Down 1.1%

NYSE ABBV opened at $214.38 on Friday. AbbVie has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market cap of $378.89 billion, a P/E ratio of 162.41, a PEG ratio of 0.89 and a beta of 0.36. The company’s 50-day simple moving average is $226.80 and its 200 day simple moving average is $216.28.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after acquiring an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its holdings in AbbVie by 0.3% during the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC lifted its position in AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after purchasing an additional 45 shares during the period. Centennial Wealth Advisory LLC grew its position in shares of AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after buying an additional 45 shares during the period. Finally, Willner & Heller LLC raised its stake in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.